Oxytocin's ability to boost nipple fluid collection for microRNA analysis explored in breast cancer pilot

Breast cancer remains a leading cause of cancer-related mortality, necessitating advanced diagnostic and prognostic tools. Its significant molecular heterogeneity, with diverse subtypes responding variably to therapies, underscores the need for precise, personalized approaches. MicroRNAs (miRNAs) are emerging as critical non-invasive biomarkers, playing key roles in gene expression regulation and disease progression, and are detectable in various biofluids. Nipple aspirate fluid (NAF) offers a unique, localized source of these biomarkers, reflecting the direct microenvironment of breast tissue. However, obtaining sufficient NAF volume can be challenging, limiting its widespread clinical utility. This pilot study investigates oxytocin, a neurohormone known for its role in milk ejection, as a potential agent to enhance NAF collection, thereby improving access to valuable miRNA profiles for breast cancer research and diagnostics.

This Phase 1 pilot study enrolled 19 women diagnosed with Stage 0 breast carcinoma (ductal carcinoma in situ, DCIS, per NCT data). The primary objective was to examine microRNA profiles from three distinct specimen types: nipple aspirate fluid (NAF), serum, and breast tissue samples collected during surgery. A secondary objective was to assess the effectiveness of oxytocin in increasing the volume of NAF collected. While the abstract does not specify the oxytocin dose, route, or timing, the intervention aimed to facilitate greater NAF yield, presumably through its known galactokinetic effects, to improve the feasibility of comprehensive miRNA biomarker analysis.

The abstract for this pilot study outlines its objectives but does not present any specific findings regarding oxytocin's effectiveness or microRNA identification. No quantitative data, statistical results, or conclusions were reported.